tiprankstipranks
Advertisement
Advertisement
Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline
PremiumCompany AnnouncementsPerspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline
2M ago
Perspective Therapeutics shareholders approve directors and governance items
Premium
Company Announcements
Perspective Therapeutics shareholders approve directors and governance items
2M ago
Perspective Therapeutics Showcases Strong Interim Radiopharma Data
Premium
Company Announcements
Perspective Therapeutics Showcases Strong Interim Radiopharma Data
2M ago
Perspective Therapeutics reports Q1 EPS (25c), consensus (30c)
PremiumThe FlyPerspective Therapeutics reports Q1 EPS (25c), consensus (30c)
3M ago
Perspective Therapeutics Highlights Q1 Progress and Strengthened Finances
Premium
Company Announcements
Perspective Therapeutics Highlights Q1 Progress and Strengthened Finances
3M ago
Perspective Therapeutics Highlights Alpha-Targeted Oncology Strategy Update
Premium
Company Announcements
Perspective Therapeutics Highlights Alpha-Targeted Oncology Strategy Update
3M ago
Perspective Therapeutics price target raised to $13 from $12 at H.C. Wainwright
PremiumThe FlyPerspective Therapeutics price target raised to $13 from $12 at H.C. Wainwright
4M ago
Perspective Therapeutics price target raised to $8 from $7 at UBS
Premium
The Fly
Perspective Therapeutics price target raised to $8 from $7 at UBS
4M ago
Perspective Therapeutics price target raised to $13 from $11 at B. Riley
Premium
The Fly
Perspective Therapeutics price target raised to $13 from $11 at B. Riley
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100